biostudies-literatureUnknown42(1)Wimmer KAustrian Breast &amp; Colorectal Study Group<h4>Background</h4>Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial.<h4>Methods</h4>Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphocJournal of experimental & clinical cancer research : CR300https://www.ebi.ac.uk/biostudies/studies/S-EPMC10644559biostudies-literatureDifferential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.PMC10644559Birnleitner HEgle DFrantal SExner RFitzal FWimmer KBago-Horvath ZBalic MOehler RRudas MFilipits MBrostjan CGnant MSinger CFSachet MBartsch RRamos CfalseDifferential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.<h4>Background</h4>Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial.<h4>Methods</h4>Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphoc2023-01-01T00:00:00Z2023 Nov2025-04-05T08:50:50.216Z2025-02-19T04:23:14.476ZS-EPMC106445593795775010.1186/s13046-023-02876-x